- Home
- GHI vs FDMT Comparison
GHI vs FDMT Comparison
Compare GHI & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- FDMT
- Stock Information
- Founded
- GHI 1998
- FDMT 2013
- Country
- GHI United States
- FDMT United States
- Employees
- GHI N/A
- FDMT N/A
- Industry
- GHI Finance: Consumer Services
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- GHI Finance
- FDMT Health Care
- Exchange
- GHI Nasdaq
- FDMT Nasdaq
- Market Cap
- GHI 285.3M
- FDMT 268.6M
- IPO Year
- GHI N/A
- FDMT 2020
- Fundamental
- Price
- GHI $12.95
- FDMT $3.69
- Analyst Decision
- GHI Strong Buy
- FDMT Buy
- Analyst Count
- GHI 3
- FDMT 10
- Target Price
- GHI $16.50
- FDMT $35.00
- AVG Volume (30 Days)
- GHI 49.4K
- FDMT 664.3K
- Earning Date
- GHI 05-07-2025
- FDMT 05-08-2025
- Dividend Yield
- GHI 11.32%
- FDMT N/A
- EPS Growth
- GHI N/A
- FDMT N/A
- EPS
- GHI 0.76
- FDMT N/A
- Revenue
- GHI $32,275,700.00
- FDMT $37,000.00
- Revenue This Year
- GHI N/A
- FDMT $11,029.73
- Revenue Next Year
- GHI N/A
- FDMT $44.15
- P/E Ratio
- GHI $17.20
- FDMT N/A
- Revenue Growth
- GHI N/A
- FDMT N/A
- 52 Week Low
- GHI $10.12
- FDMT $3.66
- 52 Week High
- GHI $16.82
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- GHI 56.37
- FDMT 35.95
- Support Level
- GHI $12.11
- FDMT $3.66
- Resistance Level
- GHI $13.29
- FDMT $4.44
- Average True Range (ATR)
- GHI 0.39
- FDMT 0.32
- MACD
- GHI 0.02
- FDMT -0.00
- Stochastic Oscillator
- GHI 71.36
- FDMT 12.17
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.